Open AccessOutcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy
Author(s) -
Oluwaseun FaladeNwulia,
Eric C. Seaberg,
Anna E. Snider,
Charles R. Rinaldo,
Steven M. Wolinsky,
Mallory D. Witt,
Chloe L. Thio
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002844
Subject(s) - medicine , hepatitis b virus , multicenter aids cohort study , hepatitis b , virology , serology , immunology , viral disease , coinfection , cohort , sida , human immunodeficiency virus (hiv) , virus , antibody
Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.